| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
- |
Next Science reports 1H FY25 Result
|
29 Aug 2025 8:53AM |
$0.145 |
$0.145 |
fallen by
0%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Product sales of US$10.5 million, down 7% on pcp.
- XPERIENCE product sales increased by 54%.
- Gross profit of US$8.7 million, gross margin increased to 83%.
- Operating expenses reduced by 17%.
- Adjusted EBITDA loss improved by 42% to US$2.8 million.
- Net operating cash outflows reduced to US$2.8 million.
- Closing cash balance of US$1.0 million.
- Majority asset sale to OSARTIS GmbH approved.
- Periprosthetic Joint Infection study underway with 2,191 patients enrolled.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Dairy Nutritionals Group (AHF) ORDINARY FULLY PAID |
Consumer Staple |
$13 |
Appendix 4E and Annual Report to Shareholders
|
29 Aug 2025 8:52AM |
$0.042 |
$0.017 |
fallen by
59.52%
|
|
AHF - Price-sensitive ASX Announcement
Full Release
Key Points
- 14% increase in revenue from ordinary activities to $7.168 million.
- 29% reduction in loss after tax to $5.261 million.
- No dividends declared for the financial year.
- Total assets decreased from $30.35 million in 2024 to $25.09 million in 2025.
- Liabilities reduced significantly from $3.62 million to $1.44 million.
- Comprehensive audited financial statements included.
- Details on directors, remuneration, and shareholding structure provided.
- Emphasis on strategic financial management including share-based payments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Dairy Nutritionals Group (AHF) ORDINARY FULLY PAID |
Consumer Staple |
$13 |
Appendix 4E and Annual Report to Shareholders
|
29 Aug 2025 8:52AM |
$0.042 |
$0.017 |
fallen by
59.52%
|
|
AHF - Price-sensitive ASX Announcement
Full Release
Key Points
- Total FY25 revenue was $7.17 million, a 14% increase over FY24.
- The infant formula business grew nearly fourfold.
- EBIT loss was reduced by 29% to $5.26 million.
- Net assets decreased to $23.65 million due to operating losses.
- The group is debt-free at the end of FY25.
- Strategic focus on expanding the infant formula market in China.
- Cost control measures reduced corporate costs by 13%.
- The group has significant growth potential in the infant formula market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
- |
Half Year Report & Appendix 4D
|
29 Aug 2025 8:52AM |
$0.145 |
$0.145 |
fallen by
0%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue declined to USD 10.49 million from USD 11.24 million year-on-year.
- Operating in North America and Australia/New Zealand as a single segment.
- Net loss of USD 4.69 million compared to USD 5.84 million previously.
- High expenses in selling, distribution, and R&D impacted financials.
- Secured a USD 4.5 million loan facility with TIGA Trading Pty Ltd.
- Recorded a comprehensive loss, including foreign currency impacts.
- Total assets at USD 9.46 million, liabilities at USD 10.02 million.
- Anticipated asset sale completion to OSARTIS in September 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Next Science Limited (NXS) ORDINARY FULLY PAID |
Health Care |
- |
Half Year Report & Appendix 4D
|
29 Aug 2025 8:52AM |
$0.145 |
$0.145 |
fallen by
0%
|
|
NXS - Price-sensitive ASX Announcement
Full Release
Key Points
- Next Science Limited reported a revenue of $10.49 million for the half-year ended 30 June 2025, a decrease from $11.24 million in the prior year.
- The company operates in a single segment across two geographical areas: North America and Australia/New Zealand.
- For the half-year, North America contributed $7.61 million in revenue and Australia/New Zealand contributed $2.87 million.
- Total comprehensive loss for the period was $4.82 million, compared to a loss of $6.03 million in the previous year.
- Cash and cash equivalents at the end of the period were $971,237, down from $1.67 million at the start of the period.
- Current liabilities increased to $4.84 million from $3.22 million, while non-current liabilities rose to $5.18 million from $2.55 million.
- The company remains focused on its core technology used in combating infections, with ongoing investments in research and development.
- Earnings per share were reported as -1.60 cents compared to -2.00 cents in the previous year.
- The company is managing a high level of accumulated losses amounting to $93.79 million as of 30 June 2025.
- Net assets have decreased significantly, reflecting a total deficiency in equity of $557,034 at the end of the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Enero Group Limited (EGG) ORDINARY FULLY PAID |
Communication Services |
$27 |
Initial Director's Interest Notice
|
29 Aug 2025 8:52AM |
$0.955 |
$0.300 |
fallen by
68.59%
|
|
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$12 |
Corporate Governance Statement & Appendix 4G
|
29 Aug 2025 8:52AM |
$0.120 |
$0.125 |
risen by
4.17%
|
|
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
- |
Appendix 4E and 2025 Annual Report
|
29 Aug 2025 8:52AM |
$0.032 |
$0.034 |
risen by
6.25%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Income from ordinary activities increased by 41.8% to AUD 1,587,462.
- Net loss reduced by 13.2% to AUD 5,332,421.
- No dividends were declared during the current financial period.
- Positive results in Phase 2a clinical trials for fibromyalgia and IBS using TRP-8802.
- R&D loan facility secured for AUD 2,600,000 for future activities.
- Total comprehensive income showed a reduction in losses compared to the prior year.
- Ongoing development of TRP-8803 with exclusive biomarker development agreement.
- The company continues to invest heavily in research and development.
- No significant environmental regulations impacted the company.
- An independence declaration was provided by BDO Audit Pty Ltd, the company's auditor.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aristocrat Leisure Limited (ALL) ORDINARY FULLY PAID |
Consumer Discretionary |
$36,441 |
Update - Notification of buy-back - ALL
|
29 Aug 2025 8:51AM |
$72.880 |
$60.790 |
fallen by
16.59%
|
|
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$12 |
FY25 Results Investor Presentation
|
29 Aug 2025 8:51AM |
$0.120 |
$0.125 |
risen by
4.17%
|
|
AFL - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue growth of 27% compared to FY24.
- Normalised NPBT of $1.4 million attributable to AF Legal Group Ltd owners, up 77%.
- Acquisition of Armstrong Criminal & Family Law practices.
- Cultural transition to a people-first and practice-led approach.
- Introduction of Project Titan, a cloud-based PMS and DMS platform.
- Strong revenue growth in Family Law segment.
- Increase of 20% in lawyers and 30% in fee earners.
- Average weekly revenue exceeded $600k in Q4 FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$12 |
FY25 Results Investor Presentation
|
29 Aug 2025 8:51AM |
$0.120 |
$0.125 |
risen by
4.17%
|
|
AFL - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 Revenue growth of 27%
- Normalised NPBT attributable to AF Legal Group owners was $1.4 million
- Acquisition of Armstrong Legal Criminal & Family Law practices
- Cultural shift towards a people-first focus
- Investment in Project Titan platform
- Net cash outflow for FY25 of $0.1 million
- Strong revenue momentum and profitability improvements
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Boss Energy Ltd (BOE) ORDINARY FULLY PAID |
Energy |
$540 |
FY2025 Financial Results
|
29 Aug 2025 8:51AM |
$1.815 |
$1.300 |
fallen by
28.37%
|
|
BOE - Price-sensitive ASX Announcement
Full Release
Key Points
- Boss Energy reported a net loss after tax of $34.2 million for FY2025.
- Total revenue for FY2025 was $75.6 million from the sale of 650Klbs of purchased uranium.
- Positive operating net cash flow of $17.4 million.
- Cash and liquid assets of $224.3 million with no debt were recorded.
- Uranium inventory amounted to 1,409Klbs, with strategic accumulation during the year.
- Average realized uranium sale price was US$78.4/lb.
- The company remains strategically under-contracted for future uranium price exposure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Boss Energy Ltd (BOE) ORDINARY FULLY PAID |
Energy |
$540 |
FY2025 Financial Results
|
29 Aug 2025 8:51AM |
$1.815 |
$1.300 |
fallen by
28.37%
|
|
BOE - Price-sensitive ASX Announcement
Full Release
Key Points
- First full financial year of production at Honeymoon and Alta Mesa.
- Net loss after tax of $34.2 million driven by non-cash impacts.
- Total revenue of $75.6 million primarily from purchased uranium sales.
- Positive operating cash flow of $17.4 million.
- Strong cash position with $224.3 million in cash and liquid assets.
- Zero debt maintained by the company.
- Inventory accumulation of 1,409,000 pounds of uranium.
- Average realized uranium sale price was US$78.4 per pound.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Enero Group Limited (EGG) ORDINARY FULLY PAID |
Communication Services |
$27 |
Director Appointment - Ian Ball
|
29 Aug 2025 8:51AM |
$0.955 |
$0.300 |
fallen by
68.59%
|
|
| Orbital Corporation Limited (OEC) ORDINARY FULLY PAID |
Industrials |
$27 |
Appendix 4G & Corporate Governance Statement
|
29 Aug 2025 8:51AM |
$0.235 |
$0.150 |
fallen by
36.17%
|
|
| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$139 |
2025 Half Year Report and Appendix 4D
|
29 Aug 2025 8:51AM |
$0.290 |
$0.320 |
risen by
10.34%
|
|
FDV - Price-sensitive ASX Announcement
Full Release
Key Points
- Group statutory revenue decreased by 5% to A$33.3 million.
- Operating expenses decreased by 10%, leading to a 71% increase in statutory EBITDA.
- Net loss after tax was A$1.7 million, a 16% increase from the previous year.
- Strong performance in the LATAM region, with Fincaraiz and Encuentra24 showing revenue and EBITDA growth.
- No dividends were declared or paid for the reporting period.
- Foreign exchange losses and other financial pressures contributed to the net loss.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$139 |
2025 Half Year Report and Appendix 4D
|
29 Aug 2025 8:51AM |
$0.290 |
$0.320 |
risen by
10.34%
|
|
FDV - Price-sensitive ASX Announcement
Full Release
Key Points
- FDV's statutory revenue for 1H FY25 was A$33.3 million, representing a 5% decrease from 1H FY24.
- Group Operating EBITDA was A$5.0 million, showing a 102% increase from the previous period.
- The company experienced growth in EBITDA despite reduced revenue, driven by efficient cost management.
- Significant items included a gain from the disposal of Hoppler and PropertyPro, and a provision for misappropriation of funds in Fincaraiz.
- The net loss after tax decreased due to cost efficiencies and strategic disposals.
- FDV operates in three regions: 360 LATAM, MENA, and FDV Asia, focusing on online classified marketplaces.
- An unrealized foreign currency translation gain was reported due to USD appreciation.
- The Directors confirmed the company’s ability to meet its obligations and declared no dividends for the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aspermont Limited (ASP) ORDINARY FULLY PAID |
Communication Services |
$17 |
Proposed issue of securities - ASP
|
29 Aug 2025 8:51AM |
$0.010 |
$1.485 |
risen by
14,750%
|
|
| Boss Energy Ltd (BOE) ORDINARY FULLY PAID |
Energy |
$540 |
Appendix 4G
|
29 Aug 2025 8:50AM |
$1.815 |
$1.300 |
fallen by
28.37%
|
|
| Enero Group Limited (EGG) ORDINARY FULLY PAID |
Communication Services |
$27 |
Enero FY25 Appendix 4G
|
29 Aug 2025 8:50AM |
$0.955 |
$0.300 |
fallen by
68.59%
|
|
| BHP Group Limited (BHP) ORDINARY FULLY PAID |
Materials |
$299,040 |
BHP Prices EMTN Bond Offer
|
29 Aug 2025 8:50AM |
$43.010 |
$58.850 |
risen by
36.83%
|
|
| Enero Group Limited (EGG) ORDINARY FULLY PAID |
Communication Services |
$27 |
Enero FY25 Corporate Governance Statement
|
29 Aug 2025 8:50AM |
$0.955 |
$0.300 |
fallen by
68.59%
|
|
| Orbital Corporation Limited (OEC) ORDINARY FULLY PAID |
Industrials |
$27 |
Full Year Statutory Accounts
|
29 Aug 2025 8:50AM |
$0.235 |
$0.150 |
fallen by
36.17%
|
|
OEC - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss of AUD 4.3 million reported for the year ending 30 June 2025.
- Revenue decreased to AUD 8.4 million from the prior year.
- Significant income from R&D rebates received.
- Total equity decreased to AUD 8.6 million due to accumulated losses.
- Investment in growth assets such as intangibles and plant equipment continued.
- Top 20 shareholders own 69.51% of the company.
- Details of directors and executive management compensation provided.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orbital Corporation Limited (OEC) ORDINARY FULLY PAID |
Industrials |
$27 |
Full Year Statutory Accounts
|
29 Aug 2025 8:50AM |
$0.235 |
$0.150 |
fallen by
36.17%
|
|
OEC - Price-sensitive ASX Announcement
Full Release
Key Points
- Orbital Corporation Limited operates in the aerospace sector, focusing on UAV propulsion systems.
- For the fiscal year ending 30 June 2025, the company reported a significant loss of $4.3 million compared to a profit of $0.1 million in the previous year.
- Revenue from continuing operations decreased by 34% to $8.2 million.
- The company raised $2 million through a rights issue in November 2024 to support new engine development and general working capital.
- A material uncertainty about Orbital's ability to continue as a going concern was highlighted.
- The company repaid a $2.4 million loan to the WA Government and is now debt-free.
- Net cash outflow from operating activities was $2.7 million, with cash and receivables at $3.3 million as of 30 June 2025.
- Orbital's market risk is influenced by factors like supply-demand dynamics and competitive manufacturing conditions.
- The company has a US facility aligned with Blue UAS compliance and has plans to re-activate it within 12 months.
- Orbital's liquidity position is strengthened by a $3 million capital raised post reporting date.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$89 |
FY25 Results Announcement
|
29 Aug 2025 8:49AM |
$0.505 |
$0.490 |
fallen by
2.97%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- SPONTAN® achieved 470% faster absorption rate than oral vardenafil tablets.
- Secured global Co-Development Agreement with Aptar Pharma.
- Expanded product development portfolio with ROXUS® and OROFLOW®.
- Established national distribution through Symbion and Men's Health Downunder.
- Maintained a cash balance of $31.8 million as of 30 June 2025.
- Increased revenue to $2.1 million due to R&D tax incentives.
- Initiated patient treatment under TGA special access schemes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
